William Taylor
speaker
421 appearances
4 recordings
2 series
first heard May 2025
last heard 8 Jul
William Taylor’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 3 in all, peaking in Jun 2026 with 2.
Appearances
And of course, Eli Lilly, to close it out, the dominant force in GLP-1 at the moment.
Another one in the space is Novo Nordisk, but they are less diversified than all of the above.
They are very much focused on GLP-1.
So those are the big players.
And I think, as you said, Ren, these have multiple pipelines constantly evolving, constantly on the run.
There's no sort of single large bet that they are making.
I mean, if you wanted to invest in the GLP-1 theme, yes, but you've got the safety net in some way that if that goes, they do have...
other areas that they're working on.
They would, but it's not all in.
Yeah.
And then if we look at the longevity-specific companies, unfortunately, a lot of them are still private and led by some of the big names that we mentioned before.
So Altos Labs, which is backed by Jeff Bezos, they're trying to reverse aging by reprogramming cells back to a younger state.
Their first human trials are expected to start this year into next year, 2027.
I wonder if they'll trial it on Jeff.
Calico is a subsidiary of Google.
They're researching aging to find treatments for age-related diseases.
But some of the listed options in this space, you've got Unity Biotechnology, BioAge Labs, and Recursion Pharmaceuticals.
Well, there's not too many of those companies back home in Australia, Ren.
We do have a healthcare sector worth $400 billion.
The largest is obviously CSL with a $58 billion market cap.
Showing 141–160 of 421 · page 8 of 22
← Previous
Next →